Anhui Anhui Anke Biotechnology (Group)Co.Ltd(300009) Engineering (Group) Co., Ltd
Independent opinions of independent directors on matters related to the 17th (Interim) meeting of the seventh board of directors of the company
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the guiding opinions on the establishment of independent director system in listed companies, the Listing Rules of gem shares of Shenzhen Stock Exchange, the Interim Measures for the administration of securities issuance of GEM listed companies and other laws, regulations and normative documents, As an independent director of Anhui Anhui Anke Biotechnology (Group)Co.Ltd(300009) Engineering (Group) Co., Ltd. (hereinafter referred to as “the company”), we express the following independent opinions on the matters related to the 17th (Interim) meeting of the seventh board of directors of the company based on the principle of objectivity and impartiality and the position of independent judgment:
1、 Independent opinions on share repurchase plan of the company
1. The company’s share repurchase plan complies with the relevant provisions of laws, regulations and normative documents such as the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the opinions on supporting listed companies to repurchase shares, and the guidelines for self discipline supervision of listed companies No. 9 – share repurchase of Shenzhen Stock Exchange, The voting procedure of the meeting of the board of directors to consider the matter is legal and compliant.
2. The company’s share repurchase is conducive to enhancing the confidence of public investors. The shares repurchased this time are intended to be used to implement equity incentive or employee stock ownership plan, which is conducive to further improve the company’s long-term incentive mechanism, fully mobilize the enthusiasm of the company’s core management team and technical backbone, and promote the long-term development of the company.
3. The capital of the company’s share repurchase this time comes from the company’s own funds. The company has sufficient own funds and payment ability, which will not have a significant adverse impact on the company’s operation, finance, debt performance ability and future development. The implementation of this repurchase plan will not lead to changes in the company’s control, affect the company’s listing status, and cause the company’s equity distribution not to meet the listing conditions.
4. The share repurchase is carried out in the form of centralized bidding transaction. The repurchase price is the market price, fair and reasonable, and there is no situation that damages the interests of the company and all shareholders (especially minority shareholders).
To sum up, the independent directors believe that the company’s share repurchase plan and decision-making procedures are legal and compliant, the repurchase plan is reasonable and feasible, in line with the interests of the company and all shareholders, and unanimously agree on the company’s share repurchase.
Independent directors: Zhang Benshan, Liu Guangfu, Zhu Weidong and Chen Mingjia February 7, 2022
